OBJECTIVE: The ectonucleotidase CD39 is an enzyme involved in adenosine production. Its surface expression on human regulatory T cells (Treg) allows for their flow-cytometry-based isolation from peripheral blood. To further develop and improve this method on a scale supporting translational studies, we introduced capture of CD39(+) Treg on magnetic immunobeads. METHODS: Peripheral blood mononuclear cells (PBMC) obtained from healthy donors were used for negative selection of CD4(+) T cells on AutoMACS using antibodies (Abs) specific for all lineage(+) cells. CD4(+)CD39(+) Treg were captured by biotin-conjugated anti-CD39 Abs and anti-biotin Ab-coated magnetic beads. Isolated CD4(+)CD39(+) T cells were phenotyped by flow cytometry for Treg-associated markers: CD39, CD73, FOXP3, CD25, CTLA-4, CCR4, CD45RO and CD121a or for the absence of CD127 and CD49d. CFSE-based proliferation assays and ATP hydrolysis were used to measure Treg functions. RESULTS: The purity, recovery and viability of the separated CD4(+)CD39(+) T cells were satisfactory. The isolated CD4(+)CD39(+) T cell population consisted of FOXP3(+)CD25(+) T cells which hydrolyzed exogenous ATP and suppressed autologous CD4(+) T cell proliferation and of FOXP3(neg)CD25(neg) T cells without suppressor function. The same two subsets were detectable by flow cytometry in normal PBMC, gating on CD4(+)CD39(+), CD4(+)CD127(neg), CD4(+)CD49d(neg) or CD4(+)CD25(high) Treg. CONCLUSION: CD4(+)CD39(+) Treg capture on immunobeads led to a discovery of two CD39(+) subsets. Similar to CD39(+) Treg in the peripheral blood, half of these cells are CD25(+)FOXP3(+) active suppressor cells, while the other half are CD25(neg)FOXP3(neg) and do not mediate suppression.
OBJECTIVE: The ectonucleotidase CD39 is an enzyme involved in adenosine production. Its surface expression on human regulatory T cells (Treg) allows for their flow-cytometry-based isolation from peripheral blood. To further develop and improve this method on a scale supporting translational studies, we introduced capture of CD39(+) Treg on magnetic immunobeads. METHODS: Peripheral blood mononuclear cells (PBMC) obtained from healthy donors were used for negative selection of CD4(+) T cells on AutoMACS using antibodies (Abs) specific for all lineage(+) cells. CD4(+)CD39(+) Treg were captured by biotin-conjugated anti-CD39 Abs and anti-biotin Ab-coated magnetic beads. Isolated CD4(+)CD39(+) T cells were phenotyped by flow cytometry for Treg-associated markers: CD39, CD73, FOXP3, CD25, CTLA-4, CCR4, CD45RO and CD121a or for the absence of CD127 and CD49d. CFSE-based proliferation assays and ATP hydrolysis were used to measure Treg functions. RESULTS: The purity, recovery and viability of the separated CD4(+)CD39(+) T cells were satisfactory. The isolated CD4(+)CD39(+) T cell population consisted of FOXP3(+)CD25(+) T cells which hydrolyzed exogenous ATP and suppressed autologous CD4(+) T cell proliferation and of FOXP3(neg)CD25(neg) T cells without suppressor function. The same two subsets were detectable by flow cytometry in normal PBMC, gating on CD4(+)CD39(+), CD4(+)CD127(neg), CD4(+)CD49d(neg) or CD4(+)CD25(high) Treg. CONCLUSION:CD4(+)CD39(+) Treg capture on immunobeads led to a discovery of two CD39(+) subsets. Similar to CD39(+) Treg in the peripheral blood, half of these cells are CD25(+)FOXP3(+) active suppressor cells, while the other half are CD25(neg)FOXP3(neg) and do not mediate suppression.
Authors: Sabine Ring; Stephen J Oliver; Bruce N Cronstein; Alexander H Enk; Karsten Mahnke Journal: J Allergy Clin Immunol Date: 2009-05-08 Impact factor: 10.793
Authors: Q Zhou; J Yan; P Putheti; Y Wu; X Sun; V Toxavidis; J Tigges; N Kassam; K Enjyoji; S C Robson; T B Strom; W Gao Journal: Am J Transplant Date: 2009-07-28 Impact factor: 8.086
Authors: T Chiacchio; R Casetti; O Butera; V Vanini; S Carrara; E Girardi; D Di Mitri; L Battistini; F Martini; G Borsellino; D Goletti Journal: Clin Exp Immunol Date: 2009-06 Impact factor: 4.330
Authors: Weihong Liu; Amy L Putnam; Zhou Xu-Yu; Gregory L Szot; Michael R Lee; Shirley Zhu; Peter A Gottlieb; Philipp Kapranov; Thomas R Gingeras; Barbara Fazekas de St Groth; Carol Clayberger; David M Soper; Steven F Ziegler; Jeffrey A Bluestone Journal: J Exp Med Date: 2006-07-03 Impact factor: 14.307
Authors: Karen M Dwyer; Silvia Deaglio; Wenda Gao; David Friedman; Terry B Strom; Simon C Robson Journal: Purinergic Signal Date: 2007-02-06 Impact factor: 3.765
Authors: Ilona Kryczek; Rebecca Liu; Guobin Wang; Ke Wu; Xiaogong Shu; Wojciech Szeliga; Linhua Vatan; Emily Finlayson; Emina Huang; Diane Simeone; Bruce Redman; Theodore H Welling; Alfred Chang; Weiping Zou Journal: Cancer Res Date: 2009-04-21 Impact factor: 12.701
Authors: Patrick J Schuler; Bernard J C Macatangay; Zenichiro Saze; Edwin K Jackson; Sharon A Riddler; William G Buchanan; Benedict B Hilldorfer; John W Mellors; Theresa L Whiteside; Charles R Rinaldo Journal: AIDS Date: 2013-06-19 Impact factor: 4.177
Authors: B Del Papa; A Pierini; P Sportoletti; S Baldoni; D Cecchini; E Rosati; E Dorillo; P Aureli; T Zei; R Iacucci Ostini; L Ruggeri; A Carotti; A Velardi; R Negrin; M F Martelli; F Falzetti; M Di Ianni Journal: Leukemia Date: 2016-04-29 Impact factor: 11.528
Authors: J Doescher; S Jeske; S E Weissinger; C Brunner; S Laban; E Bölke; T K Hoffmann; T L Whiteside; P J Schuler Journal: Strahlenther Onkol Date: 2018-04-16 Impact factor: 3.621
Authors: Patrick J Schuler; Malgorzata Harasymczuk; Carmen Visus; Albert Deleo; Sumita Trivedi; Yu Lei; Athanassios Argiris; William Gooding; Lisa H Butterfield; Theresa L Whiteside; Robert L Ferris Journal: Clin Cancer Res Date: 2014-02-28 Impact factor: 12.531
Authors: Patrick J Schuler; Malgorzata Harasymczuk; Bastian Schilling; Zenichiro Saze; Laura Strauss; Stephan Lang; Jonas T Johnson; Theresa L Whiteside Journal: Clin Cancer Res Date: 2013-10-04 Impact factor: 12.531
Authors: P J Schuler; Z Saze; C-S Hong; L Muller; D G Gillespie; D Cheng; M Harasymczuk; M Mandapathil; S Lang; E K Jackson; T L Whiteside Journal: Clin Exp Immunol Date: 2014-08 Impact factor: 4.330